Microablative Radiofrequency in the Treatment of Urinary Symptoms Associated With Genitourinary Syndrome of Menopause

Launched by CENTRO DE ATENÇÃO AO ASSOALHO PÉLVICO · Mar 27, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment option for women experiencing urinary symptoms related to Genitourinary Syndrome of Menopause (GSM), which is a condition that can cause discomfort and urinary issues due to lower estrogen levels. The trial is specifically looking at a technique called microablative radiofrequency, which is a minimally invasive procedure that may help improve symptoms like urinary incontinence. Participants will be women aged 40 to 65 who have reported urinary problems linked to GSM. To be eligible, they must not have had certain recent medical treatments or conditions that could interfere with the study.

Women who join the trial will be divided into two groups. One group will follow a pelvic floor muscle training program, which involves exercises to strengthen the muscles that help control urination. The other group will do the same exercises but will also receive the microablative radiofrequency treatment, which involves applying a numbing spray and then using a device to stimulate the vaginal area. Throughout the study, participants will fill out questionnaires and keep diaries to track their symptoms and overall satisfaction with the treatment. This trial aims to find out how effective and long-lasting the microablative radiofrequency treatment is for improving urinary symptoms in menopausal women.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Clinical complaint of urinary incontinence associated to Genitourinary Syndrome of Menopause.
• • Negative cervical oncotic cytology, within the last 3 years.
• Exclusion Criteria:
• • Patients with cognitive deficit;
• • Patients with chronic degenerative neurological diseases;
• • Post-void residue greater than 50 ml;
• • Carriers of a pacemaker and implantable cardioverter defibrillator;
• • Use of hormonal therapy (topical or systemic) starting in the 2 months prior to the initial assessment;
• • Patients undergoing brachytherapy or pelvic radiotherapy;
• • Patients that had reconstructive pelvic surgery;
• • Pregnant women.